DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Closed Posted
- Opportunity number
- HT942526ALSRPCOBA
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Unrestricted
- Points of contact
-
- eBRAP Help Desk help@ebrap.org (301) 682-5507
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Department of the Army Medical Command is soliciting applications for grants to develop and validate clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis, with a full application deadline of September 30, 2026.
Eligible applicants include extramural and intramural U.S. Department of War organizations, domestic and foreign, with independent investigators of any citizenship eligible to serve as Principal Investigator provided they hold no more than three FY26 ALSRP applications across all award mechanisms. Cost sharing is not required. The program will fund approximately seven awards totaling $7.0 million, with an individual award ceiling of $1.0 million per grant and a maximum period of performance of three years.
Projects may address clinical biomarkers, clinical outcomes, or both. Biomarkers may include susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical outcomes projects may focus on clinician-, observer-, or patient-reported, or performance outcome measures for ALS, including optimization of current measures. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, and imaging studies. Projects can target specific therapies, classes of therapeutics, or specific ALS subtypes and do not need to broadly apply to all patients. Diagnostic biomarkers distinguishing ALS from clinical mimics receive emphasis.
Community collaboration is mandatory; applicants must articulate how the proposed research question or study design was informed by the ALS lived experience community, including persons living with ALS, family members, caregivers, or community-based organizations. Clinical trials are prohibited. Applications undergo two-tier review: peer review evaluates research strategy and feasibility, scientific rationale, clinical impact, personnel qualifications, regulatory strategy, and data sharing plans; programmatic review follows. Pre-applications are due June 24, 2026. The opportunity is assigned to CFDA 12.420, Military Medical Research and Development.
Synopsis
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.
Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes. This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use.
Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.
Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the
ALS lived experience community.
Files
| File | Type | Posted |
|---|---|---|
| PKG00292623.pdf | ||
| HT942526ALSRPCOBA_GG.pdf | ||
| HT942526ALSRPCOBA_GG.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity